Molecular Partners AG

NASDAQ:MOLN

Biotechnology

Healthcare
$2.67 +0.77%

+$0.03 today

Market cap
$100.28M
Beta
0.71
P/E (TTM)
-2.0
EPS (TTM)
-$1.55
52W Low $3.41High $5.36

Volume 0.00M

Average 0.00M

MOLN Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Molecular Partners AGNASDAQ: MOLN

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was -CHF 639.3K, compared with -CHF 614.03K a year earlier. Trailing-twelve-month gross profit was -CHF 2.61M.

Context

  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near -CHF 639.3K or moves back toward the trailing-twelve-month quarterly average of -CHF 652.13K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CHF 639.3K+0.4% QoQ
Last fiscal yearDec 2025
-CHF 2.58M+93.9% YoY
LTMMar 2026
-CHF 2.61M+91.8% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.1%——
1 year+93.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

CHF · from the income statement

Latest · FY2025
(2.58M) CHF
Year-over-year change
+93.9%

Gross Profit vs competitors

How MOLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +91.8% is the 3rd highest of 7, against a peer median of +27.2%.
MOLN Competitors
Gross Profit for MOLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$3.01M USD+150.7%—94.9%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$1.69M USD—-34.1%94.7%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$149K USD+99.1%——
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$289K USD+75.2%——
PEPGPepGen Inc.LTM Mar 2026-$1.72M USD-351.6%——
NKTXNkarta, Inc.LTM Mar 2026-$2.34M USD———
MOLNMolecular Partners AGLTM Mar 2026-CHF 2.61M CHF+91.8%——
CRDFCardiff Oncology, Inc.LTM Mar 2026-$11.06M USD-20.7%+15.4%2105.7%
ALECAlector, Inc.LTM Mar 2026-$11.28M USD-289.4%-56.0%61.2%
Peer median (excluding MOLN) —+27.2%-34.1%94.8%

Competitors are the stored peer set for MOLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.33M189.56M7.04M4.97M0
Cost of Revenue55.72M50.75M47.84M47.5M2.58M
Gross Profit(46.39M)138.81M(40.81M)(42.53M)(2.58M)
Gross Margin-497.2%73.2%-579.8%-855.8%—
Research & Development55.72M50.75M48.78M48.6M40.19M
Selling, General & Admin16.91M21.82M19M17.16M14.87M
Operating Expenses72.75M72.94M20.3M18.68M50.89M
Depreciation & Amortization2.57M2.39M2.42M2.37M2.14M
EBITDA(60.66M)119M(59.52M)(51.65M)(59.49M)
EBITDA Margin-650.2%62.8%-845.6%-1039.2%—
Operating Income(63.42M)116.61M(61.11M)(61.22M)(58.12M)
Operating Margin-679.7%61.5%-868.3%-1231.7%—
Interest Income108.28K1.2M4.28M3.38M1.52M
Interest Expense608.14K648.12K49K25K18K
Other Income / Expenses(365K)1.24M(876K)7.18M(3.53M)
Income Before Tax(63.78M)117.85M(61.98M)(54.04M)(61.65M)
Pre-Tax Margin-683.6%62.2%-880.7%-1087.3%—
Income Tax Expense2K002K2K
Net Income(63.79M)117.85M(61.98M)(54.04M)(61.65M)
Net Margin-683.7%62.2%-880.7%-1087.4%—
EPS (Basic)(2.06)3.63(1.89)(1.59)(1.65)
EPS (Diluted)(2.06)3.54(1.89)(1.59)(1.65)
Weighted Avg Shares31.01M32.47M32.77M34.03M37.27M
Weighted Avg Shares (Diluted)31.01M33.27M32.77M34.03M37.27M

Molecular Partners AG

NASDAQ:MOLN

Intrinsic Alpha fair value

Locked

Current Price

$2.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.